| Course | DNRS 6501 Advanced Pathophysiology (DNP level) |
|---|---|
| Week | Week 11 |
| Paper type | Synthesis paper |
| Length | About 1,480 words, 8 pages |
| Format | APA 7 student paper |
| School | Walden University |
| Program | Doctor of Nursing Practice (DNP) |
| Updated | October 2026 |
Free sample paper for DNRS 6501 Week 11
Fibrosis as a Repair Program That Fails to Stop: A Synthesis Across Liver, Lung, and Kidney
Student Name
College of Nursing, Walden University
DNRS 6501: Advanced Pathophysiology (DNP level)
Instructor Name
Month Day, Year
Fibrosis as a Repair Program That Fails to Stop: A Synthesis Across Liver, Lung, and Kidney
Across this course, fibrosis appeared in the liver, the lung, and the kidney as if it were three different diseases. This paper argues that it is one mechanism: a wound-healing program that normally switches itself off, operating in three organs where it fails to stop. The organ decides which resident cell becomes the scar-forming cell and how much of the organ's architecture survives. The second of these, not the first, decides whether fibrosis can reverse, and that difference has direct consequences for advanced practice.
The Mechanism at Its Own Level
Fibrosis begins with injury to epithelial or endothelial cells. Damaged cells and recruited macrophages release signals, most importantly transforming growth factor beta (TGF-beta), which is held in the matrix in latent form and activated at sites of injury (Meng et al., 2016). TGF-beta and related signals convert resident mesenchymal cells into myofibroblasts, contractile cells marked by alpha-smooth muscle actin that secrete large amounts of collagen and other matrix proteins (Hinz et al., 2007). In ordinary healing, this is useful: the myofibroblast closes the defect, the matrix provides strength, and then the program ends. Myofibroblasts undergo apoptosis or revert, and matrix-degrading enzymes remodel the scar (Wynn, 2008).
Fibrosis is what happens when the ending fails. Repeated or persistent injury keeps restarting the program. The stiffened matrix itself activates latent TGF-beta and keeps myofibroblasts active, a mechanical positive feedback. Myofibroblasts in fibrotic tissue resist apoptosis. Matrix deposition outpaces degradation, and functional tissue is replaced by scar (Henderson et al., 2020). The mechanism is therefore defined not by the presence of myofibroblasts or collagen, which appear in every healing wound, but by persistence: a response that continues after the stimulus that justified it.
The Liver
In the liver, the resident cell that becomes the myofibroblast is the hepatic stellate cell. In health, stellate cells sit in the space of Disse between hepatocytes and sinusoids and store vitamin A. Chronic injury from viral hepatitis, alcohol, or fatty liver disease activates them: they lose their vitamin A stores, proliferate, contract, and deposit collagen, which narrows the sinusoids and eventually links portal areas into the bands of cirrhosis (Friedman, 2008; Tsuchida & Friedman, 2017).
The liver provides the strongest evidence that the program can be stopped and partly reversed. In an open-label follow-up of patients with chronic hepatitis B treated with tenofovir for 5 years, 176 of 348 patients with paired biopsies had regression of fibrosis, and 71 of the 96 who had cirrhosis at baseline no longer met the histologic definition of cirrhosis at year 5 (Marcellin et al., 2013). Remove the persistent injury, and activated stellate cells can undergo apoptosis or return toward quiescence, allowing matrix to be degraded (Tsuchida & Friedman, 2017). Reversal is not complete in everyone, and the study was not randomized at that stage, but the direction is clear.
The Lung
In idiopathic pulmonary fibrosis, the injury is repeated microinjury to the alveolar epithelium in susceptible individuals, followed by aberrant repair. Fibroblasts and myofibroblasts collect in fibroblastic foci beneath injured epithelium, and the alveolar architecture is replaced by dense collagen and honeycomb spaces (Richeldi et al., 2017). The mechanism is the same; the persistent stimulus is intrinsic rather than an external virus or toxin, which is why it cannot simply be removed.
The antifibrotic drugs show the limits of intervening once the program is established. Pirfenidone reduced the proportion of patients with a significant decline in forced vital capacity or death over 52 weeks (King et al., 2014), and nintedanib reduced the annual rate of decline in forced vital capacity (Richeldi et al., 2014). Both slow loss; neither restores lung that has already been replaced.
The Kidney
In the kidney, pericytes and resident fibroblasts are the main source of myofibroblasts after injury, with TGF-beta again central (Humphreys, 2018; Meng et al., 2016). Interstitial fibrosis follows many different primary injuries, from diabetic nephropathy to repeated acute kidney injury, and its extent tracks the loss of function across these causes. The pattern by now is familiar: persistent injury, persistent myofibroblast activation, and replacement of tubules and capillaries by matrix.
A Case Where the Mechanism Appears to Operate and Does Not
Organizing pneumonia tests the argument. Its histology shows buds of granulation tissue, with fibroblasts and myofibroblasts in a loose connective matrix, filling alveolar ducts and alveoli (Cordier & Cottin, 2012). On imaging and at first glance under the microscope, it looks like the fibrotic program at work. Yet organizing pneumonia usually responds to corticosteroids and resolves, often without lasting scarring, and the international classification places it apart from the fibrotic interstitial pneumonias (Travis et al., 2013).
The mechanism explains the difference. In organizing pneumonia, the myofibroblast response is inside the air spaces, the underlying alveolar walls and their architecture are largely preserved, and the response ends when the stimulus is removed or suppressed. The program ran, and then it stopped. In idiopathic pulmonary fibrosis, the program persists and the architecture is destroyed. What defines fibrosis is not the presence of scar-forming cells but the failure of the program to terminate, together with the loss of the structure that would allow the tissue to be rebuilt. This case is the reason the thesis rests on persistence and architecture rather than on the cells involved.
Why Architecture Decides Reversibility
Table 1 sets the three organs and the negative case side by side on the features the argument depends on.
Placed side by side, the three organs and the negative case suggest a single rule. Where the program can be stopped by removing the stimulus and the organ's framework survives, as in the liver with viral suppression and in organizing pneumonia, fibrosis can regress. Where the stimulus cannot be removed or the framework has been destroyed, as in established idiopathic pulmonary fibrosis and advanced renal scarring, the best available treatment slows the process. The resident cell that becomes the myofibroblast differs in each organ, but that difference predicts little about reversal. Architecture and the persistence of injury predict much more (Henderson et al., 2020).
Table 1
The Fibrotic Program in Three Organs and One Negative Case
| Setting | Main source of myofibroblasts | Persistent stimulus | Architecture when treated | Evidence on reversal |
|---|---|---|---|---|
| Liver (chronic hepatitis B) | Hepatic stellate cells | Viral replication, removable with antiviral therapy | Often partly preserved | Regression in about half of biopsied patients, including most with cirrhosis, over 5 years of suppression |
| Lung (idiopathic pulmonary fibrosis) | Resident fibroblasts in fibroblastic foci | Repeated epithelial microinjury, not removable | Destroyed in affected areas | Antifibrotics slow decline; no restoration |
| Kidney (chronic interstitial fibrosis) | Pericytes and resident fibroblasts | Varies with primary disease | Tubules and capillaries lost | Limited; progression slowed when the primary disease is controlled |
| Lung (organizing pneumonia) | Fibroblasts and myofibroblasts in air spaces | Often removable or steroid-responsive | Alveolar walls largely preserved | Usually resolves |
Read across the rows, the cell in the second column changes with every organ, while the fourth and fifth columns move together. That is the pattern the thesis claims.
Limits of the Synthesis
Three limits should be stated. First, the evidence for reversal is strongest in the liver and comes largely from biopsy studies of patients whose injury could be removed; it does not show that every fibrotic liver will regress, and the tenofovir follow-up was open-label in its later years (Marcellin et al., 2013). Second, the kidney section rests on mechanistic and observational work more than on trials of reversal, so the claim that architecture predicts reversibility there is an inference from the pattern, not a demonstrated result (Humphreys, 2018). Third, the negative case is chosen because it is clean; some patients with organizing pneumonia do develop lasting fibrosis, and in them the argument predicts, correctly, that the program persisted or the architecture was lost (Cordier & Cottin, 2012). None of these limits reverses the thesis, but each marks a place where a reader should hold it less firmly.
Consequences for Advanced Practice
The first consequence concerns timing in the lung. Because antifibrotic drugs slow loss but do not restore lung, the decision to refer a patient newly diagnosed with idiopathic pulmonary fibrosis for antifibrotic treatment should be made at diagnosis, not deferred until function has visibly fallen. Waiting to see whether the disease progresses spends lung that cannot be recovered (King et al., 2014; Richeldi et al., 2014).
The second concerns removing the stimulus in the liver. Because hepatic fibrosis can regress when the injury stops, the decision about treating the cause, antiviral therapy for hepatitis B or C or sustained support for stopping alcohol, is a decision about fibrosis itself, not only about the infection or the drinking. At the same time, histologic regression does not by itself show that every consequence of cirrhosis has reversed, so decisions about ongoing monitoring should be based on the most advanced stage the patient reached rather than on an improved result alone (Marcellin et al., 2013).
References
Cordier, J.-F., & Cottin, V. (2012). Cryptogenic organizing pneumonia. Seminars in Respiratory and Critical Care Medicine, 33(5), 462-475. https://doi.org/10.1055/s-0032-1325157
Friedman, S. L. (2008). Mechanisms of hepatic fibrogenesis. Gastroenterology, 134(6), 1655-1669. https://doi.org/10.1053/j.gastro.2008.03.003
Henderson, N. C., Rieder, F., & Wynn, T. A. (2020). Fibrosis: From mechanisms to medicines. Nature, 587(7835), 555-566. https://doi.org/10.1038/s41586-020-2938-9
Hinz, B., Phan, S. H., Thannickal, V. J., Galli, A., Bochaton-Piallat, M.-L., & Gabbiani, G. (2007). The myofibroblast: One function, multiple origins. The American Journal of Pathology, 170(6), 1807-1816. https://doi.org/10.2353/ajpath.2007.070112
Humphreys, B. D. (2018). Mechanisms of renal fibrosis. Annual Review of Physiology, 80, 309-326. https://doi.org/10.1146/annurev-physiol-022516-034227
King, T. E., Jr., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., Lederer, D. J., Nathan, S. D., Pereira, C. A., Sahn, S. A., Sussman, R., Swigris, J. J., & Noble, P. W. (2014). A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. The New England Journal of Medicine, 370(22), 2083-2092. https://doi.org/10.1056/NEJMoa1402582
Marcellin, P., Gane, E., Buti, M., Afdhal, N., Sievert, W., Jacobson, I. M., Washington, M. K., Germanidis, G., Flaherty, J. F., Schall, R. A., Bornstein, J. D., Kitrinos, K. M., Subramanian, G. M., McHutchison, J. G., & Heathcote, E. J. (2013). Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: A 5-year open-label follow-up study. The Lancet, 381(9865), 468-475. https://doi.org/10.1016/S0140-6736(12)61425-1
Meng, X.-M., Nikolic-Paterson, D. J., & Lan, H. Y. (2016). TGF-beta: The master regulator of fibrosis. Nature Reviews Nephrology, 12(6), 325-338. https://doi.org/10.1038/nrneph.2016.48
Richeldi, L., Collard, H. R., & Jones, M. G. (2017). Idiopathic pulmonary fibrosis. The Lancet, 389(10082), 1941-1952. https://doi.org/10.1016/S0140-6736(17)30866-8
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., Kim, D. S., Kolb, M., Nicholson, A. G., Noble, P. W., Selman, M., Taniguchi, H., Brun, M., Le Maulf, F., Girard, M., . . . Collard, H. R. (2014). Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. The New England Journal of Medicine, 370(22), 2071-2082. https://doi.org/10.1056/NEJMoa1402584
Travis, W. D., Costabel, U., Hansell, D. M., King, T. E., Jr., Lynch, D. A., Nicholson, A. G., Ryerson, C. J., Ryu, J. H., Selman, M., Wells, A. U., Behr, J., Bouros, D., Brown, K. K., Colby, T. V., Collard, H. R., Cordeiro, C. R., Cottin, V., Crestani, B., Drent, M., . . . Valeyre, D. (2013). An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. American Journal of Respiratory and Critical Care Medicine, 188(6), 733-748. https://doi.org/10.1164/rccm.201308-1483ST
Tsuchida, T., & Friedman, S. L. (2017). Mechanisms of hepatic stellate cell activation. Nature Reviews Gastroenterology & Hepatology, 14(7), 397-411. https://doi.org/10.1038/nrgastro.2017.38
Wynn, T. A. (2008). Cellular and molecular mechanisms of fibrosis. The Journal of Pathology, 214(2), 199-210. https://doi.org/10.1002/path.2277
What the DNRS 6501 Week 11 instructions ask for
The final week usually asks for a synthesis that connects concepts from across the course into a single argument. Rather than reviewing each system again, you identify a mechanism or principle that runs through several of them and show how it operates in each. Prompts often ask for clinical implications for advanced practice nurses and for an honest statement of where the connection breaks down. Expect a longer APA 7 paper than earlier weeks, often eight to ten pages, resting on a long list of primary and review articles. Some instructors allow you to build on earlier assignments if the argument is new. A thesis stated in the introduction gives the grader something to test. Headings should follow the argument, so a reader can see the claim develop from organ to organ.
How the DNRS 6501 Week 11 example is put together
Six pages with an argument stated on the first, not withheld for the conclusion. The mechanism is introduced once at the level it operates on rather than at the level of any one organ, which is what lets every later section of the paper stand. Three sections then show it at work in three systems the term covered, and each section is shorter than the last, because by the third the reader needs less. A fourth section handles a case where the mechanism appears to operate and does not, which is where the paper stops being a pattern-match. Twelve to fifteen references, weighted to primary work. A closing section states two consequences for advanced practice, each tied to a specific decision rather than to awareness.
DNRS 6501 Week 11 rubric: what earns full marks
Final papers separate on one question: does the writer have a claim. A paper covering four systems accurately and connecting none of them collects the knowledge credit and forfeits the synthesis criterion, which is usually the largest single share in a closing rubric. Sections read for whether the connections are mechanistic rather than thematic, since three conditions sharing a word are not three instances of a process. The negative case is where doctoral papers distinguish themselves, and its absence is rarely fatal but its presence is often decisive. Practice implications are marked on specificity, so consequences phrased as awareness or consideration score below consequences phrased as a decision that changes. Source volume matters less than distribution, and a paper citing heavily in its first two pages and thinly thereafter looks assembled rather than argued.
DNRS 6501 Week 11 help from the desk
Synthesis papers lose the most credit when they read as a tour of systems with a shared word in each heading but no argument connecting them. State your claim early and make every section test it. Another frequent problem is uneven depth, with a strong liver section and a thin kidney section; give each organ comparable treatment. Students also leave out the counterexample, though a case where the mechanism seems present and is not makes the argument far stronger. Keep the clinical section specific to advanced practice instead of listing general nursing actions. Watch the reference list, since long papers often cite works in the text that never make it to the list. Avoid introducing new organs in the conclusion. Finally, name the limits of your synthesis plainly.
Get a DNRS 6501 Week 11 example written to your instructions
Send the final paper prompt, the page range, the rubric, and the systems your section actually covered, and a synthesis built on one mechanism rather than a tour comes back to you. The first custom one is free and returns inside 24 to 48 hours. Practice hours and preceptor paperwork are your own record and are never drafted here.
More DNRS 6501 papers and DNP samples
- DNRS 6501 Week 1: Discussion Post
- DNRS 6501 Week 2: Concept Map
- DNRS 6501 Week 3: Case Analysis
- DNRS 6501 Week 4: Evidence Appraisal
- DNRS 6501 Week 5: Discussion Post
- DNRS 6501 Week 6: Pathophysiology Brief
- DNRS 6501 Week 7: Differential Analysis
- DNRS 6501 Week 8: Journal Club Critique
- DNRS 6501 Week 9: Discussion Post
- DNRS 6501 Week 10: Case Presentation
- DNRS 6521 Week 11: QI Proposal
- NURS 6914 Week 11: Reflection
- NURS 6001 Week 11: Assembled MSN success plan
- NURS 6912 Week 11: Reflection
DNRS 6501 Week 11 questions, answered
Is the last week always a paper?
Closing weeks in doctoral sequences commonly carry a larger written piece, sometimes with a final thread alongside it, but Walden publishes nothing that fixes the pattern. This page assumes a paper because that is the more demanding case. If your section closes with a presentation instead, the single-mechanism argument transfers directly onto slides.
How many systems should a synthesis cover?
Three is enough to establish a pattern and few enough to argue properly within a page limit. Coverage is not the scored quality, connection is. A paper touching six systems in six pages gives each of them a paragraph, and a paragraph is not room enough to show the same mechanism operating twice.
Can the paper reuse work from earlier weeks?
Check the prompt, since some classrooms permit building on earlier submissions and others treat it as self-plagiarism. Where it is permitted, the honest form is extension rather than reuse: an earlier case reappears under the new argument doing different work. Your classroom policy decides, and it is worth confirming before the draft rather than after.
Where can I find a free DNRS 6501 Week 11 sample paper?
The fibrosis synthesis is reproduced in full on this page, covering the liver, lung and kidney sections, the counterexample, the limits and the practice implications.
What should a DNRS 6501 Week 11 synthesis paper argue?
It should connect several systems under one mechanism and defend that link. The example argues fibrosis is a repair program that fails to stop, with architecture deciding whether the damage can reverse.